Department of Pharmacology & Toxicology

Norma C. Adragna, Ph.D., Interim Chair

Khalid Elased


Khalid Elased, Pharm.D., Ph.D.

Associate Professor

Campus Address: 238 Health Sciences
Office Phone: (937) 775-2159
Fax: (937) 775-7221


B. Pharmacy (1984), Faculty of Pharmacy, University of Khartoum, Sudan
M.Sc. (1986), School of Pharmacy, University of Bradford, England
Ph.D. (1990), School of Pharmacy, University of Strathclyde, Scotland
Postdoctoral (1991-1992) Clore Laboratory, University of Buckingham, England
Postdoctoral (1992-1996) University College London Medical School, England
Pharm.D. (2012) Ohio Northern University

Research Interests

Mechanisms of Disease-hypertension and diabetes

My current research interests are focused on understanding and manipulating the Renin-Angiotensin System (RAS) relevant to hypertension and diabetes, with a special interest in the use of Mass Spectrometry (SELDI-TOF-MS) to develop and optimize miniaturized novel assay to measure localized and circulating angiotensin converting enzyme (ACE ), ACE2 and renin.

Our recent work focused on the use of murine model of diabetes (db/db) to study the cardiovascular complications of diabetes. Our laboratory uses radiotelemetry, confocal microscopy, western blot and enzyme assay to investigate the balance of ACE/ACE2 in diabetes-induced hypertension.

Previous research interests were focused on extraction, purification and characterization of insulin mimetic molecules from Plasmodium yoelii. These molecules are related to Glycosylphosphatiylinositos (GPIs) which could have a potential as new antidiabetic agents.

Research is funded by NHLBI and WSU Boonshoft School of Medicine.

Selected Publications

Cunha TS, Farah V, Paulini J, Pazzine M, Elased KM, Marcondes FK, Claudia Irigoyen M, De Angelis K, Mirkin LD, Morris M. Relationship between renal and cardiovascular changes in a murine model of glucose intolerance. Regul Pept. 2007 Mar 1;139(1-3):1-4 [Abstract]

Farah V, Elased KM, Chen Y, Key MP, Cunha TS, Irigoyen MC, Morris M. Nocturnal hypertension in mice consuming a high fructose diet. Auton Neurosci. 2006 Dec 30;130(1-2):41-50. [Abstract]

Elased KM, Cunha TS, Gurley SB, Coffman TM, Morris M. New mass spectrometric assay for angiotensin-converting enzyme 2 activity. Hypertension. 2006 May;47(5):1010-7. [Abstract]

Elased KM, Cool DR, Morris M. Novel mass spectrometric methods for evaluation of plasma angiotensin converting enzyme 1 and renin activity. Hypertension. 2005 Oct;46(4):953-9. [Abstract]

Elased KM, Gumaa KA, de Souza JB, Playfair JH, Rademacher TW. Improvement of glucose homeostasis in obese diabetic db/db mice given Plasmodium yoelii glycosylphosphatidylinositols. Metabolism. 2004 Aug;53(8):1048-53. [Abstract]

Elased KM, Gumaa KA, de Souza JB, Rahmoune H, Playfair JH, Rademacher TW. Reversal of type 2 diabetes in mice by products of malaria parasites. II. Role of inositol phosphoglycans (IPGs). Mol Genet Metab. 2001 Jul;73(3):248-58.

Elased KM, de Souza JB, Playfair JH. Reversal of type 2 diabetes in mice by products of malaria parasites: I. Effect of inactivated parasites. Metabolism. 2000 Jul;49(7):937-41. [Abstract]

Elased KM, Taverne J, Playfair JH. Malaria, blood glucose, and the role of tumour necrosis factor (TNF) in mice. Clin Exp Immunol. 1996 Sep;105(3):443-9.

Elased KM, Playfair JH. Reversal of hypoglycaemia in murine malaria by drugs that inhibit insulin secretion. Parasitology. 1996 Jun;112 ( Pt 6):515-21. [Abstract]

Elased K, De Souza JB, Playfair JH. Blood-stage malaria infection in diabetic mice. Clin Exp Immunol. 1995 Mar;99(3):440-4. [Abstract]

Elased K, Playfair JH. Hypoglycemia and hyperinsulinemia in rodent models of severe malaria infection. Infect Immun. 1994 Nov;62(11):5157-60. [Abstract]

Elased KM, Furman BL. Acute stress-induced hyperinsulinemia in the pertussis toxin-treated rat: possible role of humoral beta-cell-tropic factors. Metabolism. 1994 Oct;43(10):1221-5. [Abstract]

Selected Patents

  1. Treatment of Diabetes:
    British patent application no. 9618290.2
    Inventors: Elased, K.M., De Souza, J.B. and Playfair, J.H.L..
    Patent Number W098/09637 Filed March 1998
    U.S. Patent Application Serial No. US 6,214,357, Filed April 10, 2001
  2. Phosphoglycan messengers and their medical uses (lipidaemia).
    Inventers: Elased, K.M., Guuma, K.A., De Souza, J.B., Rahmoune, H. and Rademacher, T.W.
    British patent application No. 0015627.3 Filed June 2000.
    Published in Patents and Designs Journal (August 16, 2000, No. 5805:3559)
  3. Screening Assay for Enzymes Involved in Patho-physiology Using SELDI-TOF Mass Spectrometry
    Inventers: Elased, K.M., and Morris, M.
    Attorney Docket No. WRU 0269 PA/40878.369
    U.S. Patent Application Serial No. 11/292,806 Filed December 2, 2005